Article révisé par les pairs
Titre:
  • Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
Auteur:Baselga, José; Gómez, Patricia; Greil, Richard; Braga, Sofia; Climent, Miguel Angel; Wardley, Andrew; Kaufman, Bella; Stemmer, Salomon M; Pêgo, António; Chan, Arlene; Goeminne, Jean Charles; Graas, Marie-Pascale; Kennedy, M John; Ciruelos Gil, Eva Maria; Schneeweiss, Andreas; Zubel, Angela; Groos, Jutta; Melezínková, Helena; Awada, Ahmad
Informations sur la publication:Journal of clinical oncology, 31, 20, page (2586-2592)
Statut de publication:Publié, 2013-07
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Antibodies, Monoclonal, Humanized -- administration & dosage -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effects
Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology
Cisplatin -- administration & dosage -- adverse effects
Confidence Intervals
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Maximum Tolerated Dose
Middle Aged
Multivariate Analysis
Neoplasm Invasiveness -- pathology
Neoplasm Staging
Prognosis
Proportional Hazards Models
Receptor, Epidermal Growth Factor -- drug effects -- metabolism
Receptors, Estrogen -- drug effects -- metabolism
Receptors, Progesterone -- drug effects -- metabolism
Risk Assessment
Survival Analysis
Treatment Outcome
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0732-183X
info:doi/10.1200/JCO.2012.46.2408
info:pii/JCO.2012.46.2408
info:scp/84883858492
info:pmid/23733761

Documents en relation

DI-fusion